Top

Published in:

01-04-2013 | Interventional

Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases

Authors: Charlotte E. N. M. Rosenbaum, M. A. A. J. van den Bosch, W. B. Veldhuis, J. E. Huijbregts, M. Koopman, M. G. E. H. Lam

Published in: European Radiology | Issue 4/2013

Abstract

Objective

Yttrium-90 radioembolisation (Y90-RE) is recommended for unresectable, chemorefractory liver-dominant disease; however, the incidence of extrahepatic disease (EHD) is high. FDG-PET may have additional value to CT in demonstrating EHD. Our aim was to evaluate the added diagnostic value of FDG-PET to abdominal CT and study the influence of FDG-PET findings on treatment decisions.

Methods

All consecutive patients with colorectal cancer liver metastases (CRCLM) referred for Y90-RE were included. Patients who underwent both CT and FDG-PET in the diagnostic workup were selected. Imaging reports were scrutinised for documented sites of EHD, and changes of management due to FDG-PET findings were determined.

Results

A total of 42 patients were included. Findings on CT and FDG-PET matched in 20 patients (no EHD, n = 15; identical EHD, n = 5). In 4 patients, lesions detected on CT were not FDG-avid, and in 18 patients, FDG-PET showed more lesions than CT (P < 0.05). In 7/42 patients (17 %) a change of management was made based on the additional FDG-PET findings, i.e. exclusion from Y90-RE treatment (n = 6) and change in treatment plan (whole liver rather than segmental treatment, n = 1).

Conclusions

In patients with CRCLM referred for Y90-RE, FDG-PET showed significantly more EHD and led to a considerable change of management.

Key Points

• Yttrium-90 radioembolisation is a locoregional treatment for liver tumours

• Detection of extrahepatic lesions, for which CT is widely used, is crucial

• FDG-PET shows significantly more extrahepatic lesions compared to CT

• FDG-PET findings led to a considerable change in treatment decisions

Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A (2012) Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. Am J Clin Oncol 35:167–177PubMedCrossRef

Kennedy AS, McNeillie P, Dezarn WA et al (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494–1500PubMedCrossRef

Murthy R, Brown DB, Salem R et al (2007) Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18:553–561, quiz 562PubMedCrossRef

Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19:951–959PubMedCrossRef

Dezarn WA, Cessna JT, DeWerd LA et al (2011) Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys 38:4824–4845PubMedCrossRef

Lewandowski RJ, Sato KT, Atassi B et al (2007) Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 30:571–592PubMedCrossRef

Hendlisz A, Eynde MVD, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694PubMedCrossRef

Kennedy A, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65:412–425PubMedCrossRef

Stubbs RS, O’Brien I, Correia MM (2006) Selective internal radiation therapy with 90y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696–703PubMedCrossRef

10.

Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85PubMedCrossRef

11.

Gray B, Van Hazel GA, Hope M et al (2001) Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720PubMedCrossRef

12.

Chua TC, Bester L, Saxena A, Morris DL (2010) Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 137:865–873PubMedCrossRef

13.

Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331PubMedCrossRef

14.

Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34:337–341PubMedCrossRef

15.

Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMedCrossRef

16.

Giammarile F, Bodei L, Chiesa C et al (2011) EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 38:1393–1406PubMedCrossRef

17.

Denecke T, Rühl R, Hildebrandt B et al (2008) Planning transarterial radioembolization of colorectal liver metastases with yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques. Eur Radiol 18:892–902PubMedCrossRef

18.

Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R (2012) Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol 35:91–99PubMedCrossRef

19.

Mulcahy MF, Lewandowski RJ, Ibrahim SM et al (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858PubMedCrossRef

20.

Bester L, Meteling B, Pocock N et al (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:96–105PubMedCrossRef

21.

Nace GW, Steel JL, Amesur N et al (2011) Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol 2011:1–9. doi:10.1155/2011/571261 CrossRef

22.

Povoski SP, Fong Y, Sgouros SC, Kemeny NE, Downey RJ, Blumgart LH (1998) Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann Surg Oncol 5:9–15PubMedCrossRef

23.

Kronawitter U, Kemeny NE, Heelan R, Fata F, Fong Y (1999) Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer 86:229–235PubMedCrossRef

24.

Strasberg SM, Dehdashti F (2010) Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer. J Surg Oncol 102:955–959PubMedCrossRef

25.

Huebner RH, Park KC, Shepherd JE et al (2000) A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41:1177–1189PubMed

26.

Ruers TJM, Wiering B, van der Sijp JRM et al (2009) improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 50:1036–1041PubMedCrossRef

27.

Wiering B, Adang EMM, van der Sijp JRM et al (2010) Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun 31:938–944PubMedCrossRef

28.

Vach W, Hoilund-Carlsen PF, Gerke O, Weber WA (2011) Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med 52:77S–85SPubMedCrossRef

Title: Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases
Authors: Charlotte E. N. M. Rosenbaum
M. A. A. J. van den Bosch
W. B. Veldhuis
J. E. Huijbregts
M. Koopman
M. G. E. H. Lam
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: European Radiology / Issue 4/2013
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-012-2693-x

At a glance: The STEP trials

Springer Medicine

Added value of FDG-PET imaging in the diagnostic workup for yttrium-90 radioembolisation in patients with colorectal cancer liver metastases

Abstract

Objective

Methods

Results

Conclusions

Key Points

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Key Points

Please log in to get access to this content

Other articles of this Issue 4/2013

Prevalence and patterns of anatomical risk factors in patients after patellar dislocation: a case control study using MRI

Differentiation of benign from malignant solid breast masses: comparison of two-dimensional and three-dimensional shear-wave elastography

A method for improving iodine contrast enhancement in abdominal computed tomography: experimental study in a pig model

Evaluation of shearwave elastography for the characterisation of focal liver lesions on ultrasound

Peritoneal inclusion cysts: clinical characteristics and imaging features

Volumetric MR-guided high-intensity focused ultrasound ablation of uterine fibroids: treatment speed and factors influencing speed